Replies to post #99152 on Biotech Values

[go seek]

Perhaps GILD will shop in Cambridge... IDIX

[pastemp]

It is also bullish for ZGEN.

[mcbio]

GILD - Seeking Alpha Transcript snip related to HCV partnering

http://seekingalpha.com/article/215497-gilead-sciences-inc-q2-2010-earnings-call-transcript?part=qanda

Geoff Meacham – JPMorgan

Just a follow-up to the answer about Phase II programs, does the hiring of Dr. McHutchison speak to anything with respect to therapeutic areas. I know you guys have had obviously hep C products in the portfolio for a while, and would that be something that you will look externally or would you put more resources behind the current pipeline?

Norbert Bischofberger

Jeff, I would say the answer to that is both. We’re constantly looking externally as to what’s available, and of course, with John having joined us, we have more insights and knowledge as to what is really available and what would fit our pipeline.

But we also want to put a lot more emphasis on our own programs as well, and now we recently made the decision to close our Durham facility, which allows us to concentrate everything here in Foster City, and bring both the clinical development and research efforts in close proximity, I think that will greatly accelerate the programs.

[tony111]

Are GS9256 and GS9190 considered to be less potent when compared with other drugs in their class? Does it suggest an all oral cocktail will require at least 3 compounds? As a ZYMO long I am biased to believe GILD's failure is bullish for interferon lambda.